Canada's Painkiller Shortage Extends Into New Year
Critical shortages of hydromorphone and other essential pain medications continue to plague Canadian pharmacies, leaving patients scrambling as supply chain issues persist.
Critical shortages of hydromorphone and other essential pain medications continue to plague Canadian pharmacies, leaving patients scrambling as supply chain issues persist.
The FDA's principal deputy commissioner, Dr. Namandjé Bumpus, resigns following federal probe into undisclosed concerns about her conduct, marking significant leadership shakeup.
In a landmark move reshaping the consumer healthcare landscape, Kimberly-Clark announces its acquisition of Kenvue, the company behind Tylenol and other household brands, in a staggering US$48.7 billion transaction that creates a new industry powerhouse.
In a landmark healthcare deal, Kimberly-Clark acquires Kenvue, the consumer health giant behind Tylenol, Band-Aid and Listerine, reshaping the North American healthcare landscape.
Health Canada issues urgent recall for specific blood pressure medications containing potentially carcinogenic nitrosamine impurity. Learn which lots are affected and what steps to take.
Pharmaceutical giant Eli Lilly reports explosive growth driven by Mounjaro and Zepbound, creating intense investor competition and reshaping the obesity treatment landscape.
Pharmaceutical giants and startups race to develop next-generation weight-loss treatments as demand soars and market valuations skyrocket in this healthcare revolution.
Global pharmaceutical leader Boehringer Ingelheim secures exclusive license from Kyowa Kirin to develop innovative autoimmune disease treatment, targeting conditions like lupus and rheumatoid arthritis with novel therapeutic approach.
A former Melita pharmacy manager faces consequences after being convicted of multiple professional misconduct charges, including improper prescription practices and record-keeping failures.
A Kamloops pharmacist faces consequences after admitting to making false statements to their regulatory body, resulting in a four-month suspension and financial penalty.